Showing results (111-120 of 447) with videos related to
Sort By:
Pageof 45
Thrombosis and Haemostasis|January 29, 2016
D-dimer and factor VIIa in atrial fibrillation - prognostic values for cardiovascular events and effects of anticoagulation therapy. A RE-LY substudyAgneta Siegbahn, Jonas Oldgren, Ulrika Andersson, et al.BMJ Open|April 2, 2016
Effectiveness of implementation strategies in improving physician adherence to guideline recommendations in heart failure: a systematic review protocolHarriette G C Van Spall, Deepti Shanbhag, Itzhak Gabizon, et al.Age and Ageing|November 22, 2015
Efficacy and safety of apixaban compared with aspirin in the elderly: a subgroup analysis from the AVERROES trialKuan H Ng, Olga Shestakovska, Stuart J Connolly, et al.Europace : European Pacing, Arrhythmias, and Cardiac Electrophysiology : Journal of the Working Groups on Cardiac Pacing, Arrhythmias, and Cardiac Cellular Electrophysiology of the European Society of Cardiology|September 28, 2013
Effect of dronedarone on clinical end points in patients with atrial fibrillation and coronary heart disease: insights from the ATHENA trialRon Pisters, Stefan H Hohnloser, Stuart J Connolly, et al.Journal of Stroke and Cerebrovascular Diseases : the Official Journal of National Stroke Association|July 24, 2012
Stroke risk and efficacy of apixaban in atrial fibrillation patients with moderate chronic kidney diseaseJohn W Eikelboom, Stuart J Connolly, Peggy Gao, et al.Annals of Internal Medicine|November 2, 2011
Net clinical benefit of adding clopidogrel to aspirin therapy in patients with atrial fibrillation for whom vitamin K antagonists are unsuitableStuart J Connolly, John W Eikelboom, Jennifer Ng, et al.The Canadian Journal of Cardiology|January 29, 2013
Canadian Cardiovascular Society guidelines on the use of cardiac resynchronization therapy: evidence and patient selectionDerek V Exner, David H Birnie, Gordon Moe, et al.Circulation. Cardiovascular Genetics|February 28, 2012
Effect of PON1 Q192R genetic polymorphism on clopidogrel efficacy and cardiovascular events in the Clopidogrel in the Unstable Angina to Prevent Recurrent Events trial and the Atrial Fibrillation Clopidogrel Trial with Irbesartan for Prevention of Vascular EventsGuillaume Paré, Stephanie Ross, Shamir R Mehta, et al.American Heart Journal|October 31, 2006
Risks and benefits of combining aspirin with anticoagulant therapy in patients with atrial fibrillation: an exploratory analysis of stroke prevention using an oral thrombin inhibitor in atrial fibrillation (SPORTIF) trialsGreg C Flaker, Michael Gruber, Stuart J Connolly, et al.The New England Journal of Medicine|February 14, 2009
Effect of dronedarone on cardiovascular events in atrial fibrillationStefan H Hohnloser, Harry J G M Crijns, Martin van Eickels, et al.Pageof 45